GBM AGILE Global Adaptive Trial Master Protocol:An International, Seamless Phase II/III ResponseAdaptive Randomization Platform Trial Designed ToEvaluate Multiple Regimens In Newly Diagnosedand Recurrent Glioblastoma (GBM)
MD Anderson Study Status
Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
John de Groot
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.